tiprankstipranks
Trending News
More News >
Aquestive Therapeutics (AQST)
NASDAQ:AQST
US Market

Aquestive Therapeutics (AQST) Stock Statistics & Valuation Metrics

Compare
2,165 Followers

Total Valuation

Aquestive Therapeutics has a market cap or net worth of $315.86M. The enterprise value is $241.64M.
Market Cap$315.86M
Enterprise Value$241.64M

Share Statistics

Aquestive Therapeutics has 99,327,930 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99,327,930
Owned by Insiders13.48%
Owned by Institutions20.01%

Financial Efficiency

Aquestive Therapeutics’s return on equity (ROE) is 0.73 and return on invested capital (ROIC) is -36.79%.
Return on Equity (ROE)0.73
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-36.79%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee405.36K
Profits Per Employee-310.82K
Employee Count142
Asset Turnover0.57
Inventory Turnover2.96

Valuation Ratios

The current PE Ratio of Aquestive Therapeutics is -7.00. Aquestive Therapeutics’s PEG ratio is 0.36.
PE Ratio-7.00
PS Ratio0.00
PB Ratio-4.28
Price to Fair Value-5.13
Price to FCF-5.53
Price to Operating Cash Flow-5.35
PEG Ratio0.36

Income Statement

In the last 12 months, Aquestive Therapeutics had revenue of 57.56M and earned -44.14M in profits. Earnings per share was -0.51.
Revenue57.56M
Gross Profit39.69M
Operating Income-30.77M
Pretax Income-44.15M
Net Income-44.14M
EBITDA-26.62M
Earnings Per Share (EPS)-0.51

Cash Flow

In the last 12 months, operating cash flow was -48.77M and capital expenditures -265.00K, giving a free cash flow of -49.04M billion.
Operating Cash Flow-48.77M
Free Cash Flow-49.04M
Free Cash Flow per Share-0.49

Dividends & Yields

Aquestive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.86
52-Week Price Change21.35%
50-Day Moving Average2.72
200-Day Moving Average3.70
Relative Strength Index (RSI)70.99
Average Volume (3m)1.49M

Important Dates

Aquestive Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date

Financial Position

Aquestive Therapeutics as a current ratio of 4.68, with Debt / Equity ratio of -64.23%
Current Ratio4.68
Quick Ratio4.36
Debt to Market Cap0.11
Net Debt to EBITDA1.26
Interest Coverage Ratio-1.83

Taxes

In the past 12 months, Aquestive Therapeutics has paid -14.00K in taxes.
Income Tax-14.00K
Effective Tax Rate<0.01

Enterprise Valuation

Aquestive Therapeutics EV to EBITDA ratio is -10.34, with an EV/FCF ratio of -7.66.
EV to Sales4.78
EV to EBITDA-10.34
EV to Free Cash Flow-7.66
EV to Operating Cash Flow-7.70

Balance Sheet

Aquestive Therapeutics has $68.66M in cash and marketable securities with $39.13M in debt, giving a net cash position of -$29.52M billion.
Cash & Marketable Securities$68.66M
Total Debt$39.13M
Net Cash-$29.52M
Net Cash Per Share-$0.30
Tangible Book Value Per Share-$0.69

Margins

Gross margin is 59.06%, with operating margin of -53.46%, and net profit margin of -76.68%.
Gross Margin59.06%
Operating Margin-53.46%
Pretax Margin-76.70%
Net Profit Margin-76.68%
EBITDA Margin-46.24%
EBIT Margin-47.49%

Analyst Forecast

The average price target for Aquestive Therapeutics is $7.59, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.59
Price Target Upside138.68% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast5.29%
EPS Growth Forecast-37.31%

Scores

Smart Score8
AI Score44
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis